VR Logo

Lineage Cell Therapeutics Inc. (LCTX) download report


Healthcare | Biotechnology & Pharma Research

Lineage Cell Therapeutics Inc. (LCTX) Premium Coverage

52 Stocks to buy right now

Join Value Research Stock Advisor now and be among the first to discover Stock Ideas

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

About The Company

Business: Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally.

IPO Date: 06-Mar-1992

CEO, Pres & Director: Mr. Brian M. Culley M.A., M.B.A.

Chief Financial Officer: Mr. Kevin Leon Cook

Listing: NYSE: LCTX

Country: United States

Headquarters: Carlsbad, CA

Website: https://www.lineagecell.com

Key Facts

Market cap: $244.41 Mln

Revenue (TTM): $7.08 Mln

Earnings (TTM): $-48.69 Mln

Cash: $79.94 Mln

Total Debt: $2.56 Mln

Insider's Holding: 4.67%

Liquidity: Low

52 Week range: $1.10 - 3.00

Shares outstanding: 169,727,008

10 Years Aggregate:

  • CFO: $-311.57 Mln
  • EBITDA: $-338.92 Mln
  • Net Profit: $-256.73 Mln

Stock Performance

Time Period Lineage Cell Therapeutics (LCTX) S&P BSE Sensex S&P Small-Cap 600
YTD-44.08-9.49-17.79
1 month9.60-2.87-2.72
3 months-0.72-8.59-12.17
1 Year-50.900.81-15.82
3 Years8.2510.397.14
5 Years-15.5011.116.20
10 Years-11.2512.0010.33
As on 24-Jun-2022